Summer is not officially here, according to the calendar, but the first long weekend of the season brings thoughts of beaches, mountains, travel, relaxation, lazy days and active ones. No matter what floats your boat over summer vacation, a good book should never be far away. With that in mind, assembled once again for your reading pleasure is BioWorld’s Summer Reading List – our 9th annual edition. Be forewarned: Our respondents dug deep this year, tackling a variety of thoughtful and complex issues. You won’t find any fluff on these pages, but you’ll certainly find opportunities to be dazzled and...
Disclosure of promising top-line data from a phase II dose-optimization trial evaluating the therapeutic vaccine GEN-003 in genital herpes boosted shares of Genocea Biosciences Inc. (NASDAQ:GNCA) 8.8 percent Wednesday, aided by a price target hike from Piper Jaffray & Co.
Just three years old, Braeburn Pharmaceuticals is assembling a pipeline of drugs using a tried-and-true recipe: The company is applying implantable and injectable technology to reformulate off-patent drugs and bring them to market using the 505(b)(2) pathway.
Cortendo AB made clear that it's no longer a sleepy little Swedish biotech by acquiring two late-stage candidates targeting acromegaly and other endocrinology applications and tacking on another $33.2 million in a private placement.
Denali Therapeutics Inc. is seeking to surmount challenges where other biopharmas have failed by scaling the rugged terrain of neurodegenerative disease.
Tonix Pharmaceuticals Holding Corp. took a giant step toward moving its lead compound, TNX-102, across the goal line by launching the phase III AFFIRM study in patients with fibromyalgia.
Pfizer Inc.'s give-back of rights to Remoxy, the long-acting, tamper-resistant form of oxycodone developed by Pain Therapeutics Inc., put the Austin, Texas-based company in a world of hurt last October, despite its insistence that the pharma partner's decision was based on an internal pipeline prioritization rather than a problem with the drug.
Privately held Curemark LLC launched an additional phase III trial of its chymotrypsin modulator, CM-AT, that will enroll a broad population of children with autism, ages 3 to 8, after a previous phase III of the compound met the endpoints in the same age group of children with autism who had low levels of chymotrypsin, a digestive enzyme.
A week after reporting first quarter financials and continuing to tout GCS−100 as a first-in-class galectin-3 inhibitor to treat chronic kidney disease (CKD), La Jolla Pharmaceutical Co. is ditching the candidate, along with follow-on LJPC−1010, its second-generation galectin-3 inhibitor.
